Skip to main content
. 2011 Jan 19;9:2. doi: 10.1186/1476-7961-9-2

Figure 2.

Figure 2

Change in FcεRI expression during treatment with omalizumab. Whole blood was collected from the patient prior to the first treatment with omalizumab (day 0) and prior to each subsequent treatment day. Total FcεRI expression was examined in whole blood by flow cytometry using dual staining with basophil cell surface markers anti-CD123 (IL-3r) and anti-FcεRI.